Sopharma AD (BUL:SFA)

Market Cap	1.12B
Revenue (ttm)	2.27B
Net Income (ttm)	88.47M
Shares Out	166.36M
EPS (ttm)	0.50
PE Ratio	13.35
Forward PE	n/a
Dividend	0.15 (2.22%)
Ex-Dividend Date	n/a

Volume	15,150
Average Volume	10,338
Open	6.70
Previous Close	6.76
Day's Range	6.68 - 6.76
52-Week Range	5.52 - 6.76
Beta	-0.23
RSI	78.21
Earnings Date	May 30, 2025

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices...

• Industry: Pharmaceutical Preparations
• Founded: 1933
• Employees: 5,599
• Stock Exchange: Bulgarian Stock Exchange
• Ticker Symbol: SFA

Financial Performance

In 2024, Sopharma AD's revenue was 2.14 billion, an increase of 13.27% compared to the previous year's 1.89 billion. Earnings were 77.85 million, a decrease of -18.89%.